Concurrent chemotherapy using taxane plus cisplatin versus cisplatin alone in high-risk nasopharyngeal carcinoma patients with suboptimal response to induction chemotherapy

BACKGROUND: Detectable Epstein–Barr virus (EBV) DNA levels and unsatisfactory tumor response to induction chemotherapy (IC) could be used to guide the risk-adapted treatment strategy of locoregionally advanced nasopharyngeal carcinoma (LANPC) before concurrent chemoradiotherapy. We aim to compare th...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ya-Ni, Chen, Yu-Pei, Li, Ji-Bin, Lu, Tai-Xiang, Han, Fei, Chen, Chun-Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262618/
https://www.ncbi.nlm.nih.gov/pubmed/37323188
http://dx.doi.org/10.1177/17588359231177016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10262618/
https://www.ncbi.nlm.nih.gov/pubmed/37323188
http://dx.doi.org/10.1177/17588359231177016

Ejemplares similares